Yahoo Finance

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

PITTSBURGH, June 2, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 ...
Yahoo Finance

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating ...
Healio

Vision tests under mesopic, glare conditions may predict night-driving difficulty

Please provide your email address to receive an email when new articles are posted on . Mesopic visual acuity and disability glare index accounted for the greatest variation in night-driving ...
Healio

YAG enhancement improves pupil size after pinhole pupilloplasty

Pinhole pupilloplasty is a surgical procedure that aims to narrow the pupil to pinhole size to impart greater depth of focus ...
Seeking Alpha

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating ...